Advertisement

TXG

10x Genomics, Inc.

Healthcare · USD

Set alert

Price alert · TXG

All alert types
70.11 USD -11.44 -14.03%
As of Oct 30, 2026 Extended hours 69.80 -0.44%
Bid
70.10 × 2
Ask
70.11 × 2
67.42 Day range 75.77
12.44 52-week range 97.74
YTD
+329.86%
1 year
+463.59%
Open
73.65
Prev close
81.55
Mkt cap
9.13B
Vol
5.22M
Avg vol
3.37M
EPS
-0.59
P/E
0.00
Div yield
0.00%
More statistics
Low
67.42
High
75.77
Forward P/E
913.53
Beta
1.99
Short ratio
3.09
Inst. own
116.04%
Dividend
0.00
Ex-div date
Earnings
Nov 5, 2026
50-d avg
74.05
200-d avg
40.33
1y target
77.50

5D chart

Chart tools
Interval
TXG five-day price chart67.472.577.682.787.8Oct 26Oct 27Oct 28Oct 29Oct 30

Key statistics

Market cap
9.13B
Enterprise value
10.15B
Trailing P/E
0.00
Forward P/E
913.53
PEG ratio
0.00
Price / sales
14.79
Price / book
11.05
EPS (TTM)
-0.59
Beta
1.99
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-12.18%
Revenue (TTM)
616.91M
Revenue growth
-12.70%
Free cash flow
179.66M
Total cash
552.03M
Total debt
78.80M
Return on equity
-9.40%
Shares outstanding
120.21M
Short % of float
14.33%
50-day average
74.05
200-day average
40.33

Analyst view

Consensus: buy

Buy
Price target (mean) 77.50 +10.5% upside
Target (low)
50.00
Target (mean)
77.50
Target (high)
110.00
Ratings (0m) 18 6 buy · 12 hold · 0 sell
  • Strong buy1
  • Buy5
  • Hold12
  • Sell0
  • Strong sell0

Next earnings

Nov 5, 2026

Expected Nov 5, 2026. Consensus EPS estimate -0.02.

Earnings history

Financials — quick view

All financials
TXG Revenue — quarterly 151.04M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
TXG Net income — quarterly -17.93M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
TXG EPS — quarterly -0.14
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

TXG recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 5, 2026Sep 30, 2026-0.267———
Aug 6, 2026Jun 30, 2026-0.24308-0.14+0.10+42.41%
May 7, 2026Mar 31, 2026-0.29-0.10+0.19+65.52%
Feb 12, 2026Dec 31, 2025-0.19-0.13+0.06+31.58%
Nov 6, 2025Sep 30, 2025-0.07-0.22-0.15-214.29%
Aug 7, 2025Jun 30, 2025-0.350.28+0.63+180.00%

Upgrades / downgrades

TXG analyst upgrades and downgrades
DateFirmActionFromTo
Oct 13, 2026TD CowenmainHoldHold
Oct 13, 2026Morgan StanleymainEqual-WeightEqual-Weight
Oct 12, 2026Canaccord GenuitymainBuyBuy
Oct 7, 2026BarclaysmainOverweightOverweight
Sep 29, 2026Leerink PartnersmainMarket PerformMarket Perform
Sep 28, 2026Piper SandlermainNeutralNeutral

About 10x Genomics, Inc.

10x Genomics, Inc. develops and sells instruments, consumables, and software for analyzing biological systems in the United States, rest of the Americas, Europe, the Middle East, Africa, China, and the rest of the Asia Pacific. The company offers Chromium platform, a single cell portfolio that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; and QuantumScale single cell RNA and single cell methylation kits. It also provides Visium platform, a spatial analysis platform that uses high density DNA arrays to encode the physical location of biological analytes within a sample. This platform includes HD WT panel gene expression, and HD 3' gene expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides. In addition, the company offers Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section without the need for conventional sequencing; and slides and reagents. Further, it provides various software products comprising Cell Ranger, a scRNA-seq processing pipeline in scientific literature; Loupe Browser, which enables intuitive single-cell, spatial, and multiomic data visualization; and Xenium Explorer that enables intuitive in situ data visualization, which allows researchers to explore subcellular gene expression, spatial organization, and tissue-scale patterns. The company serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.

Sector
Healthcare
Industry
Medical Devices
Country
United States

News

Your note

Sign in to keep a note on TXG — it syncs with the Stock Master app.

Insider holders

TXG insider holders
InsiderRelationLatest transactionDateShares held
HINDSON BENJAMIN JPresidentSaleAug 23, 2026488,182
KOSARAJU SRIDHARDirectorStock Award(Grant)Jun 3, 202668,278
MATEO ALAN V.DirectorStock Award(Grant)Jun 3, 202685,877
POPOVITS KIMBERLY JDirectorStock Award(Grant)Jun 3, 202637,445
SAXONOV SERGE WILSONChief Executive OfficerSaleSep 21, 20261,335,170
STUELPNAGEL JOHN RDirectorSaleSep 2, 2026328,436

Institution ownership

TXG institution ownership
Holder% heldSharesValueReported
FMR, LLC14.67%17,629,2661.23BJun 29, 2026
Blackrock Inc.8.99%10,804,070756.72MJun 29, 2026
ARK Investment Management, LLC8.32%10,003,057700.61MJun 29, 2026
Vanguard Portfolio Management LLC5.81%6,982,492489.05MJun 29, 2026
Quantinno Capital Management, LP4.55%5,469,698383.10MJun 29, 2026
Vanguard Capital Management LLC4.23%5,082,594355.98MJun 29, 2026

Fund ownership

TXG fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.94%3,528,683247.15MJun 29, 2026
ARK ETF Trust-ARK Innovation ETF2.62%3,148,101220.49MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF2.52%3,032,629212.41MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund2.12%2,548,523178.50MJun 29, 2026
ARK ETF Trust-ARK Genomic Revolution ETF2.08%2,498,429174.99MSep 29, 2026
Fidelity Select PORT.s-Select Medical Technology and Devices PORT.1.99%2,392,772167.59MAug 30, 2026
Advertisement